[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retractile-capsulitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retractile-capsulitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100645418","phase-2-a-pilot-superiority-study-comparing-the-efficacy-of-a-combination-of-a-glenohumeral-intra-articular-injection-with-a-suprascapular-nerve-block-versus-a-glenohumeral-intra-articular-corticosteroid-injection-in-retractile-capsulitis-100645418",false,"NCT07680504","A Pilot Superiority Study Comparing the Efficacy of a Combination of a Glenohumeral Intra-articular Injection With a Suprascapular Nerve Block Versus a Glenohumeral Intra-articular Corticosteroid Injection in Retractile Capsulitis","EBLOUIR","Inclusion Criteria:\n\n* Patients with shoulder pain and stiffness that has persisted for at least 2 months but less than 12 months, with a loss of passive range of motion in at least 2 planes (lateral rotation, medial rotation, abduction, forward flexion) of at least 30 degrees compared to the contralateral side\n* Patients between the ages of 18 and 65\n* Patients enrolled in a social security program\n\nExclusion Criteria:\n\n* \\- Corticosteroid injection into the affected shoulder \\\u003C 4 months ago\n* History of any surgery on the affected shoulder within the past 12 months\n* Patients with a neuromuscular condition (neurological deficit) or shoulder condition (arthropathy) that could interfere with the assessment of the primary endpoint\n* Signs or risk of infection (bacterial-like infection and\u002For fever and\u002For antibiotic use)\n* Poor skin condition of the affected shoulder\n* Anticoagulation with VKAs or anti-Xa agents, or active bleeding disorder or one in remission for less than 5 years (malignant hematologic disorders, myelodysplasia, autoimmune thrombocytopenia) or chemotherapy (antiplatelet agents permitted except prasugrel and clopidogrel)\\*\n* Uncontrolled hypertension,\n* Decompensated diabetes or diabetes at risk of decompensation,\n* Contraindications to diprosten, Kenacort, or lidocaine\n* Psychiatric conditions that may be exacerbated by corticosteroids\n* Pregnant or breastfeeding women, or women who refuse to use effective contraception\n* Individuals belonging to a vulnerable group as defined by Regulation (EU) No. 536\u002F2014 and French law (See section 4.4 of the protocol) - - Patients unable to comply with the protocol requirements (see Section 4.4 of the protocol)\n* Patients participating in another clinical research protocol involving a drug or medical device\n* Patients who refuse to participate in the study","ALL","18 Years","65 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Drug Trial\n\n* Single-center\n* Exploratory trial\n* Controlled\n* Randomized\n* Double-blind\n* Prospective\n\nObjective is to compare improvements in shoulder function at 3 months between the group receiving an intra-articular injection combined with a suprascapular nerve block and the group receiving an intra-articular injection combined with a placebo block 19 patients in the Experimental Group (block with corticosteroid and intra-articular injection on Day 0) 19 patients in the Control Group (block with saline and intra-articular injection on Day 0)\n\n* Total duration: 36 months\n* Recruitment period: 24 months\n* Treatment duration per patient: 2 ultrasound-guided procedures on Day 0\n* Follow-up duration per patient: 12 months after the procedure\n\nAt J0 : Under ultrasound guidance, inject 2 mL of lidocaine into the notch, then:\n\n* Experimental Group: 8 mL of 1% lidocaine into the notch with 1 mL of betamethasone,\n* Control Group: 9 mL of saline into the notch.\n\nDuring these consultations, M1, M3, M6 et M12 , the following examinations will be performed:\n\n* Clinical examination of the painful shoulder, including measurement of range of motion\n* Visual Analog Scale (VAS) for pain\n* Quick Dash, OSS, and SPADI self-report questionnaires completed by the patient\n* Recording of complications\n* Questions about returning to work",[27],"Retractile Capsulitis",[29,30],"suprascapular nerve block","intra-articular injection","NOT_YET_RECRUITING","2026-06-25",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":32,"type":21},{"date":38,"type":21},"2029-06-25",{"name":40,"class":41},"Nantes University Hospital","OTHER"]